Clinicians eager to incorporate the latest retinal diagnostic technology now have another option for optical coherence tomography angiography (OCT-A), especially those who already have the Heidelberg Spectralis OCT device.
Heidelberg Engineering recently announced the FDA has cleared a new OCT angiography module for the Spectralis portfolio. Clinicians in the market for a new OCT and those with existing Spectralis upgradeable devices can incorporate this diagnostic tool into their practice. OCT-A allows for noninvasive evaluation of retinal and choroidal vascular abnormalities using three-dimensional visualization of perfused vasculature structures, the company says.
More information available in the full press release here.